Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 21;12:753653. doi: 10.3389/fphar.2021.753653

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Cheng, Duan, Zhou, Zhao, Yi, Liu, Deng, Li, Zeng, Peng, Song, Lin, Yang and Chen.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of the MCID response rate between different main inhalation therapy in patients with symptomatic COPD. Note: (A) MCID response rate in all patients with symptomatic COPD. (B) MCID response rate in group B patients with symptomatic COPD. (C) MCID response rate in group D patients with symptomatic COPD. For comparison, the chi-squared test was used for categorical variables. ** indicates p-values <0.01, *** indicates p-values <0.001. Abbreviations: MCID, minimum clinically important difference; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.